Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174030 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Phase 2 study of Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 269
- Enrollment target
- 20
- Study locations
NCT01174030 is a Phase 2 study of Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 269 participants, above the 231-participant average among 23 other Rosacea trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT01174030, a Phase 2 study of Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 269 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema associated with rosacea.
Conditions Studied
Interventions
- DRUG Vehicle Gel
- DRUG CD07805/47 Gel
Study Locations (20)
North Carolina
- Dermatology Laser & Vein Specialists - Charlotte
- Dermatology Consulting Services - High Point
Oregon
- Oregon Dermatology & Research Center - Portland
- Oregon Medical Research - Portland
Pennsylvania
- Philadelphia Institute of Dermatology - Fort Washington
- DermDox - Hazleton
Texas
- Arlington Center for Dermatology - Arlington
- Dermatology Treatment & Research Center - Dallas
Arkansas
- Burke Pharmaceutical Research - Hot Springs
California
- University of California at San Francisco - San Francisco
Georgia
- Meda Phase, Inc - Newnan
Kentucky
- Dermatology Specialists PC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174030
The ClinicalTrials.gov registry entry for NCT01174030 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 231-participant average among 23 other Rosacea trials with a reported enrollment target (16% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Gel is the first listed.
NCT01174030 reports 20 study locations spanning 16 distinct geographic areas - top geographies include North Carolina, Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01174030 about?
NCT01174030 is a clinical study titled "Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea". The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema a...
What is the current status of trial NCT01174030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 269 participants. The study started on 2010-08. Estimated completion is 2011-01.
What conditions does trial NCT01174030 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT01174030?
The interventions under investigation include: Vehicle Gel (DRUG), CD07805/47 Gel (DRUG).
Who is sponsoring clinical trial NCT01174030?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01174030 being conducted?
This trial has 20 study locations across Arkansas, California, Georgia, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
Rosacea and Ivermectin
COMPLETED · Phase 2
-
AGN-199201 for the Treatment of Erythema With Rosacea
COMPLETED · Phase 2
-
A Study of DER 45-EV Gel to Treat Rosacea
COMPLETED · Phase 2
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.